Europe Scar Treatment Market Overview, Share, Segment Analysis and Forecast by 2023

The Europe scar treatment market size was valued at $5.2 billion in 2016, which is expected to reach $9.8 billion by 2023, growing at a CAGR of 9.6% during the forecast period (2017-2023). Topical scar treatment is expected to witness highest growth during the forecast period in the European scar treatment market due to increasing disposable income, rising prevalence of chronic wounds and availability of different types of topical scar treatment products. Topical scar treatment is followed by surface scar treatment, laser scar treatment, injectable scar treatment, invasive surgical scar treatment. Among the different types of scar, post-surgical scar was the most widely treated type of scar in Europe in 2016, followed by acne scar, keloid scar & hypertrophic scar, contracture scar, and stretch mark. The contribution of hospital in the European scar treatment market was the highest in 2016 mainly due to continuously developing reimbursement structure in the region.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/europe-scar-treatment-market/report-sample

The prevalence of skin problems is on rise due to rising levels of pollution and ozone depletion which causes direct exposure to UV radiations leading to sunburns and diminished elasticity of skin. The prevalence of wounds is rising in the Europe and so is the disposable income of European households enabling them to opt for cosmetic surgeries and expensive scar treatments available in the market. Due to rising expenditure on personal care in the U.K., various skin treatment product manufacturers are launching advanced products in the country. For instance, in May 2012, Avita Medical developed ReCell Spray-On Skin system for treating chronic wounds, burns and scars in the U.K. The technological advancements and rising awareness about skin related problems and their available treatments are also key factors leading to the growth of the European scar treatment market. For instance, in February 2017, Lumenis Ltd. supported International Scar Treatment Conference in Israel, held in Tel Aviv, focused on spreading awareness about the interdisciplinary approach for successful management of scars.

According to the European Wound Management Association (EWMA), around 4 million wound cases are reported every year in the Europe. This in turn, is driving the demand for scar treatment products in the region. Furthermore, according to the OECD, the German household disposable income was $34,887.8 in 2014, compared to $34,286.2 in 2013. The increase in the disposable income enables people to opt for new and expensive treatments, that are available in the market for treating scar. Furthermore, the growing online cosmetic products industry in the region is adding to the growth of the scar treatment market in Europe.

Browse report at: https://www.psmarketresearch.com/market-analysis/europe-scar-treatment-market

Some of the key players operating in the European scar treatment market include Merz GmbH & Company KGAA, Mölnlycke Health Care AB, Smith & Nephew Plc, Syneron Medical Ltd., Lumenis Ltd., L'oreal S.A, H&R Healthcare Ltd., Avita Medical, Arbonne International, and Laverana GmbH & Co.KG.

Source: P&S Intelligence

Cancer/Tumor Profiling Market Analysis, Share, Growth Drivers and Forecast by 2023

The cancer/tumor profiling market size is projected to reach $87.1 billion by 2023, growing at a CAGR of 19.0% during 2017-2023. The market is growing mainly due to the increasing number of new cancer cases, rising utility of biomarkers in tumor profiling, rising availability of funding for cancer research and increasing demand for next generation sequencing for cancer profiling.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/cancer-profiling-market/report-sample

The players in the market are developing different biomarkers based on what is to be detected in a patient. For instance, Caris Life Sciences, develops several biomarkers that are based on IHC, that detects the level of protein expression, translocations and fusions, ISH, amplifications, detects gene deletions, NGS, rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome, and fragment analysis, that detects changes in RNA or DNA to indicate the absence or presence of genetic marker. Due to this precise detection using biomarkers for the cancer-causing agent, there is an increase in the use of biomarkers for cancer profiling and thereby driving the growth of the cancer/tumor profiling market.

The key players in the cancer/tumor profiling market are collaborating with other firms to expand their market share. In September 2017, Indivumed, GmbH and Helomics Corp. entered into a partnership to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cancer-profiling-market

Some of the other key players operating in the cancer/tumor profiling market include Illumina, Inc., NeoGenomics Inc., Caris Life Sciences, Inc., Oxford Gene Technology, HTG Molecular Diagnostics, Inc., RiboMed Biotechnologies, Inc., QIAGEN N.V. and NanoString Technologies, Inc.

Source: P&S Intelligence

Wound Dressing Industry Analysis, Share, Growth Drivers and Forecast to 2023

Global wound dressing market size is expected to reach $17.3 billion by 2023. The market is mainly driven by increasing volume of surgeries; rising number of road accidents; surge in number of burn cases; growing incidence of chronic wounds such as diabetic foot ulcer, pressure ulcer, and venous ulcer; and rising prevalence of diabetes.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/wound-dressings-market/report-sample

Advanced wound dressings and traditional wound dressings are the two types of wound dressings available in the market. Between these, the demand for advanced wound dressings is expected to witness higher growth, at a CAGR of 8.0%, during the forecast period. This is because advanced wound dressings have better efficacy than traditional wound dressings such as bandage, gauze, sponge, abdominal pad in wound healing.

Among the various advanced wound dressings, the market for superabsorbent wound dressings is expected to witness the fastest growth, with a CAGR of 10.5%, during the forecast period, mainly driven by the superior healing property of these products.

The key players operating in the wound dressing industry are launching various advanced wound dressing products in order to strengthen their position in the advanced wound dressing market. For instance, in 2017, ConvaTec Group Plc launched AQUACEL, a surgical dressing for reducing surgical site infection. It has a thin adhesive layer, to aid conformability for specific types of surgical wounds such as cesarean section and lumbar spine surgery, and also provides antimicrobial protection.

Browse report at: https://www.psmarketresearch.com/market-analysis/wound-dressings-market

Some of the other key players operating in the wound dressing market are 3M Company, Medtronic plc, Smith & Nephew plc, Hollister Incorporated, Integra Lifesciences Corporation, Johnson & Johnson, DeRoyal Industries Inc., Mölnlycke Health Care AB and DermaRite Industries LLC.

Source: P&S Intelligence